EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration

<p>Subgroup analyses underscore favorable clinical p</p>
<p>The post <a href="https://forextv.com/top-news/eyepoint-pharmaceuticals-announces-two-presentations-of-topline-data-with-additional-subgroup-analyses-from-the-phase-2-davio-2-clinical-trial-of-eyp-1901-for-the-treatment-of-wet-age-related-macular/">EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration</a> appeared first on <a href="https://forextv.com">ForexTV</a>.</p>